Antibody-mediated protection against Ebola virus

The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding

(2018) Liam B. King et al.   Cell Host & Microbe

Correlative microscopy for structural microbiology

(2018) Stuart C Howes et al.   CURRENT OPINION IN MICROBIOLOGY

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

(2018) Kristen E Pascal et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

(2018) Martin R. Gaudinski et al.   PLOS MEDICINE

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy

(2018) Juan C. Almagro et al.   Frontiers in Immunology

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

(2018) Erica Ollmann Saphire et al.   CELL

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

(2018) Bronwyn M. Gunn et al.   Cell Host & Microbe

Systems serology for evaluation of HIV vaccine trials

(2017) Margaret E. Ackerman et al.   IMMUNOLOGICAL REVIEWS

Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice

(2017) Caitlin M. Gillis et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Considering aspects of the 3Rs principles within experimental animal biology

(2017) Lynne U. Sneddon et al.   JOURNAL OF EXPERIMENTAL BIOLOGY

Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function

(2017) Oliver Popp et al.   mAbs

How to turn competitors into collaborators

(2017) Erica Ollmann Saphire et al.   NATURE

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

(2017) Paul J. Carter et al.   NATURE REVIEWS DRUG DISCOVERY

Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections

(2017) Eleonora Cimini et al.   PLoS Neglected Tropical Diseases

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

(2017) Anna Bootz et al.   PLoS Pathogens

Antibody therapies for the prevention and treatment of viral infections

(2017) Georgina Salazar et al.   npj Vaccines

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

(2016) Kensei Tobinai et al.   ADVANCES IN THERAPY

Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection

(2016) Xin Gong et al.   CELL

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection

(2016) Carole J. Henry Dunand et al.   Cell Host & Microbe

Harnessing Fc receptor biology in the design of therapeutic antibodies

(2016) Peter Sondermann et al.   CURRENT OPINION IN IMMUNOLOGY

Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth

(2016) Jinghe Huang et al.   IMMUNITY

Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae

(2016) Sanjay Ram et al.   IMMUNOBIOLOGY

Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches

(2016) Falk Nimmerjahn   JOURNAL OF CLINICAL IMMUNOLOGY

Structural basis of potent Zika–dengue virus antibody cross-neutralization

(2016) Giovanna Barba-Spaeth et al.   NATURE

Correlated fluorescence microscopy and cryo-electron tomography of virus-infected or transfected mammalian cells

(2016) Cheri M Hampton et al.   Nature Protocols

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

(2016) D. Corti et al.   SCIENCE

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

(2016) J. Misasi et al.   SCIENCE

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface

(2016) Rob N. de Jong et al.   PLOS BIOLOGY

Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination

(2016) Alison E. Mahan et al.   PLoS Pathogens

Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination

(2016) Alison E. Mahan et al.   PLoS Pathogens

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies

(2016) Jesper Pallesen et al.   Nature Microbiology

Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody

(2015) Takao Hashiguchi et al.   CELL

Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus

(2015) Andrew I. Flyak et al.   CELL

Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine

(2015) Yan Zhou et al.   CURRENT OPINION IN IMMUNOLOGY

Obinutuzumab: A Review of Its Use in Patients with Chronic Lymphocytic Leukaemia

(2015) Sheridan M. Hoy   DRUGS

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

(2015) E. M. Lee et al.   HAEMATOLOGICA

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization

(2015) Stylianos Bournazos et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies

(2015) Edgar Davidson et al.   JOURNAL OF VIROLOGY

Antibody responses to envelope glycoproteins in HIV-1 infection

(2015) Dennis R Burton et al.   NATURE IMMUNOLOGY

Swift antibodies to counter emerging viruses: Fig. 1.

(2015) Dennis R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

(2015) Davide Corti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune correlates of vaccine protection against HIV-1 acquisition

(2015) Lawrence Corey et al.   Science Translational Medicine

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

(2015) E. M. Lee et al.   HAEMATOLOGICA

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function

(2014) Amy W. Chung et al.   AIDS

A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

(2014) Anita Kumar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity

(2014) Stylianos Bournazos et al.   CELL

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

(2014) M. Jack Borrok et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

(2014) Xiangguo Qiu et al.   NATURE

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

(2014) Daphne A Stanley et al.   NATURE MEDICINE

Structures of protective antibodies reveal sites of vulnerability on Ebola virus

(2014) Charles D. Murin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies

(2014) Caitlin Gillis et al.   Frontiers in Immunology

Role of Fc-mediated antibody function in protective immunity against HIV-1

(2013) George K. Lewis   IMMUNOLOGY

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

(2013) Margaret E. Ackerman et al.   JOURNAL OF CLINICAL INVESTIGATION

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

(2013) C Kellner et al.   LEUKEMIA

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions

(2013) Christian Kellner et al.   METHODS

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

(2013) Davide Corti et al.   NATURE

Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail

(2013) J. Pettitt et al.   Science Translational Medicine

Isotype and glycoform selection for antibody therapeutics

(2012) Roy Jefferis   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Ebola virus entry requires the host-programmed recognition of an intracellular receptor

(2012) Emily Happy Miller et al.   EMBO JOURNAL

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody

(2012) Seung Y. Chu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Marketing approval of mogamulizumab

(2012) Alain Beck et al.   mAbs

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

(2012) P. Mark Hogarth et al.   NATURE REVIEWS DRUG DISCOVERY

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease

(2012) J. M. Dye et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

(2012) G. G. Olinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

(2012) R. de Alwis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection

(2012) Xiangguo Qiu et al.   PLoS Neglected Tropical Diseases

Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus

(2012) Gopi S. Mohan et al.   PLoS Pathogens

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

(2011) Aasia Ghazi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus

(2011) Holly M. Horton et al.   JOURNAL OF IMMUNOLOGY

Advances in the assessment and control of the effector functions of therapeutic antibodies

(2011) Xu-Rong Jiang et al.   NATURE REVIEWS DRUG DISCOVERY

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

(2011) L. Zeitlin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin  5 1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

(2010) G. Li et al.   CANCER RESEARCH

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

(2010) Robert M Anthony et al.   Current Opinion in Organ Transplantation

Biochemical and Structural Characterization of Cathepsin L-Processed Ebola Virus Glycoprotein: Implications for Viral Entry and Immunogenicity

(2010) C. L. Hood et al.   JOURNAL OF VIROLOGY

Production of therapeutic antibodies with controlled fucosylation

(2010) Naoko Yamane-Ohnuki et al.   mAbs

Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms

(2010) Devon J. Shedlock et al.   VIROLOGY

A Forward Genetic Strategy Reveals Destabilizing Mutations in the Ebolavirus Glycoprotein That Alter Its Protease Dependence during Cell Entry

(2009) A. C. Wong et al.   JOURNAL OF VIROLOGY

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses

(2009) Xiangguo Qiu et al.   PLoS One

The impact of Fc engineering on an anti-CD19 antibody: increased Fc  receptor affinity enhances B-cell clearing in nonhuman primates

(2008) J. Zalevsky et al.   BLOOD

Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells

(2008) J. O. Richards et al.   MOLECULAR CANCER THERAPEUTICS

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor

(2008) Jeffrey E. Lee et al.   NATURE

Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure

(2008) Richard Strasser et al.   PLANT BIOTECHNOLOGY JOURNAL

Generation of biologically contained Ebola viruses

(2008) P. Halfmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Complex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light Chain

(2007) Jeffrey E. Lee et al.   JOURNAL OF MOLECULAR BIOLOGY

Glycosylation of Recombinant Antibody Therapeutics

(2005) Royston Jefferis   BIOTECHNOLOGY PROGRESS